Johnson & Johnson (JNJ)
| Market Cap | 626.09B +50.0% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.6% |
| Shares Out | 2.41B |
| PE Ratio | 30.12 |
| Forward PE | 23.13 |
| Dividend | $5.36 (2.06%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 5,943,356 |
| Open | 261.23 |
| Previous Close | 261.81 |
| Day's Range | 258.36 - 264.15 |
| 52-Week Range | 171.81 - 274.90 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 272.50 (+4.89%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $272.5, which is an increase of 4.89% from the latest price.
News
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will partici...
3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26
Walmart ($WMT), Johnson & Johnson ($JNJ), and Chevron ($CVX) are three Dividend Aristocrat stocks with a Strong Buy consensus rating on Wall Street and ex-dividend dates ranging between August 19…
Jim Cramer highlights 5 investing themes — and the stocks to buy for each
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital On...
Johnson & Johnson price target raised to $287 from $270 at Guggenheim
Guggenheim raised the firm’s price target on Johnson & Johnson to $287 from $270 and keeps a Buy rating on the shares after making updates to its model following a…
3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26
For investors seeking dependable dividend income, International Business Machines ($IBM), Johnson & Johnson ($JNJ), and Coca-Cola ($KO) stand out. According to TipRanks’ Dividend Aristocrat tool, the ...
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fires...
Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman
Johnson & Johnson announced that Jennifer Taubert will retire from her position as Executive Vice President, EVP, Worldwide Chairman, Innovative Medicine. Taubert will be succeeded by Tom Cavanaugh wh...
Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medi...
Johnson & Johnson Transcript: Investor update
OTTAVA launches as a table-integrated robotic surgery platform, targeting expansion in the U.S. and globally with a differentiated design, automation, and digital ecosystem. Early clinical results show strong workflow and efficiency benefits, with a roadmap for rapid indication and instrument expansion.
Johnson & Johnson price target raised to $282 from $272 at Wells Fargo
Wells Fargo raised the firm’s price target on Johnson & Johnson to $282 from $272 and keeps an Overweight rating on the shares. The firm is lower its EPS estimates…
Johnson & Johnson removed from US Conviction List at Goldman Sachs
Goldman Sachs analysts removed Johnson & Johnson from the firm’s US Conviction List as part of its monthly update while keeping a Buy rating on the shares. Published first on…
Inside J&J's Lab to Create a Simpler Robotic Surgery Device
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race...
Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review
Johnson & Johnson announced that the FDA has granted Priority Review to the supplemental Biologics License Application for Rybrevant Faspro, or subcutaneous amivantamab and hyaluronidase-lpuj for adul...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients...
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary...
Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36
The company states: “The combination of these two transactions is also expected to reduce the Company’s 2027 Adjusted Operational EPS and Adjusted EPS by approximately $1.36, consisting of approximate...
Johnson & Johnson lowers 2026 profit forecast
Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedici...
Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68
Prior guidance was $11.50-$11.65. On July 29, 2026, Johnson & Johnson announced the completion of the acquisition of Firefly Bio, Inc. and the entry into strategic agreements and collaboration with…
Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B
Cuts FY26 operating margin view to down 75bps from up 75bps vs. prior year.
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CA...
Explainer: Can J&J finally put the talc litigation behind it?
After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that cou...
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit
Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle